Close Menu
  • Home
  • United States
  • World
  • Politics
  • Business
  • Lifestyle
  • Entertainment
  • Health
  • Science
  • Tech
  • Sports
  • More
    • Web Stories
    • Editor’s Picks
    • Press Release

Subscribe to Updates

Get the latest USA news and updates directly to your inbox.

What's On
Official Cause of Death Revealed for Gypsy Rose Blanchard’s Ex Ken Urker

Official Cause of Death Revealed for Gypsy Rose Blanchard’s Ex Ken Urker

November 16, 2026
The Patrick Mahomes reason why Raiders fans have no worry about Fernando Mendoza

The Patrick Mahomes reason why Raiders fans have no worry about Fernando Mendoza

November 16, 2026
One-third of caregivers don’t know about this potentially deadly heart condition — despite seeing the warning signs

One-third of caregivers don’t know about this potentially deadly heart condition — despite seeing the warning signs

November 16, 2026
Facebook X (Twitter) Instagram
Trending
  • Official Cause of Death Revealed for Gypsy Rose Blanchard’s Ex Ken Urker
  • The Patrick Mahomes reason why Raiders fans have no worry about Fernando Mendoza
  • One-third of caregivers don’t know about this potentially deadly heart condition — despite seeing the warning signs
  • OpenAI CEO Sam Altman empathizes with Nvidia’s Jensen Huang: ‘Heroes have flaws’
  • Gavin Newsom reveals secret trip to Ukraine, takes dig at Trump
  • Gregory Bovino to speak at Rutgers as anti-ICE counterprotest planned
  • Which ‘Virgin River’ Stars Are — And Aren’t — Returning for Season 8 After Multiple Cast Exits?
  • Dak Prescott’s ex-fiancée Sarah Jane Ramos seemingly tunes out Cowboys’ brutal loss to 49ers
  • Privacy
  • Terms
  • Advertise
  • Contact Us
Join Us
USA TimesUSA Times
Newsletter Login
  • Home
  • United States
  • World
  • Politics
  • Business
  • Lifestyle
  • Entertainment
  • Health
  • Science
  • Tech
  • Sports
  • More
    • Web Stories
    • Editor’s Picks
    • Press Release
USA TimesUSA Times
Home » New Chinese weight-loss drug produces bigger results than Wegovy in under a year
New Chinese weight-loss drug produces bigger results than Wegovy in under a year
Health

New Chinese weight-loss drug produces bigger results than Wegovy in under a year

News RoomBy News RoomNovember 16, 20260 ViewsNo Comments

The race for the tiniest waist just got even more competitive.

New clinical trial results suggest a Chinese-made weight-loss drug could help people shed nearly 18% of their body weight in under a year.

The findings suggest the newcomer could one day outperform some of the biggest names in the booming GLP-1 market, including Wegovy and Mounjaro.

In the 48-week trial, researchers from Fudan University in Shanghai recruited 567 adults who were overweight or obese and divided them into four groups.

Three groups received weekly injections of ribupatide at doses of 2 milligrams, 4 milligrams or 6 milligrams, while the fourth received a placebo.

Behind the experimental drug is Chinese pharmaceutical giant Hengrui, which partnered with US biotech firm Kailera Therapeutics to bring ribupatide to markets outside China.

Ribupatide works by mimicking two hormones naturally produced in the gut that help regulate appetite, digestion and blood sugar.

It’s a similar approach to that used by Eli Lilly’s blockbuster drugs Mounjaro and Zepbound. But ribupatide has been designed to bind more tightly to its targets and stay active in the body longer, potentially extending its effects throughout the week.

Everyone in the study — including those given placebo shots — also followed a lifestyle program that included dietary counseling and recommendations to get at least 150 minutes of moderate exercise each week.

After 48 weeks, those taking the lowest dose of ribupatide had lost an average of 10.7% of their starting body weight. Those on the 4-milligram dose shed 16.4%, while participants taking the highest dose lost a whopping 17.7%.

The placebo group lost just 1.4%.

The numbers are in the same ballpark as — and potentially higher than — those seen with Wegovy. In a separate clinical trial, people taking a 2.4 mg dose of the popular GLP-1 shot lost an average of 14.9% of their body weight over a longer period of 68 weeks.

And ribupatide’s results could have been even more impressive. Weight loss hadn’t started to level off among participants taking the two highest doses by the end of the 11-month study, suggesting they could have lost even more with longer treatment.

And the benefits extended beyond the scale.

Although none of the participants had diabetes, researchers found that those taking ribupatide had reductions in blood sugar. They also saw improvements in blood pressure and cholesterol.

Their waistlines shrank, too — an important measurement because abdominal fat is linked to an increased risk of heart disease and other health problems.

The participants taking ribupatide saw their waist measurements drop by between 9 and 14 centimeters, compared with just 2.5 centimeters among those on the placebo.

The drug wasn’t without some familiar side effects, though. Like other GLP-1s, ribupatide most commonly caused digestive problems, including nausea, vomiting and diarrhea. The researchers said the symptoms were generally mild to moderate and occurred most often as participants increased their doses.

Study authors said their results are promising and come amid a need for more pharmacological treatment options as obesity continues to plague millions of people.

The problem is particularly acute in the US, where roughly four in 10 adults have obesity and an even larger share are overweight. Among children and teenagers ages 2 to 19, just over 21% have obesity.

It’s no wonder Americans’ appetite for weight-loss injections shows little sign of slowing. A September Gallup survey found that 11% of US adults were currently taking a GLP-1 medication for weight loss, up from just 3% in 2024.

Overall, 15% said they had taken one of the blockbuster drugs at some point in their lives — a jump of nine percentage points in just two years.

Share. Facebook Twitter LinkedIn Telegram WhatsApp Email

Keep Reading

One-third of caregivers don’t know about this potentially deadly heart condition — despite seeing the warning signs

One-third of caregivers don’t know about this potentially deadly heart condition — despite seeing the warning signs

The ‘disease of kings’ is making a comeback — the painful symptoms and how it’s triggered

The ‘disease of kings’ is making a comeback — the painful symptoms and how it’s triggered

Mom loses nearly 200 pounds after fears of ruining daughter’s wedding photos

Mom loses nearly 200 pounds after fears of ruining daughter’s wedding photos

Gas station pill leaves man, 32, suffering from septic shock, hearing loss — and the condition that killed NYC marathon runner

Gas station pill leaves man, 32, suffering from septic shock, hearing loss — and the condition that killed NYC marathon runner

How scientists are learning to rewire brains — and what it could mean for traumatic memories

How scientists are learning to rewire brains — and what it could mean for traumatic memories

Feel dizzy at Whole Foods? You may have ‘supermarket syndrome’

Feel dizzy at Whole Foods? You may have ‘supermarket syndrome’

A guide to fall allergies: What causes them, symptoms — and how to get relief

A guide to fall allergies: What causes them, symptoms — and how to get relief

Adding 3 simple foods to your diet could lead to a longer life: expert

Adding 3 simple foods to your diet could lead to a longer life: expert

The supposedly safer plastic chemical linked to smaller babies: study

The supposedly safer plastic chemical linked to smaller babies: study

Add A Comment
Leave A Reply Cancel Reply

Editors Picks

The Patrick Mahomes reason why Raiders fans have no worry about Fernando Mendoza

The Patrick Mahomes reason why Raiders fans have no worry about Fernando Mendoza

November 16, 2026
One-third of caregivers don’t know about this potentially deadly heart condition — despite seeing the warning signs

One-third of caregivers don’t know about this potentially deadly heart condition — despite seeing the warning signs

November 16, 2026
OpenAI CEO Sam Altman empathizes with Nvidia’s Jensen Huang: ‘Heroes have flaws’

OpenAI CEO Sam Altman empathizes with Nvidia’s Jensen Huang: ‘Heroes have flaws’

November 16, 2026
Gavin Newsom reveals secret trip to Ukraine, takes dig at Trump

Gavin Newsom reveals secret trip to Ukraine, takes dig at Trump

November 16, 2026

Subscribe to News

Get the latest USA news and updates directly to your inbox.

Latest News
Gregory Bovino to speak at Rutgers as anti-ICE counterprotest planned

Gregory Bovino to speak at Rutgers as anti-ICE counterprotest planned

November 16, 2026
Which ‘Virgin River’ Stars Are — And Aren’t — Returning for Season 8 After Multiple Cast Exits?

Which ‘Virgin River’ Stars Are — And Aren’t — Returning for Season 8 After Multiple Cast Exits?

November 16, 2026
Dak Prescott’s ex-fiancée Sarah Jane Ramos seemingly tunes out Cowboys’ brutal loss to 49ers

Dak Prescott’s ex-fiancée Sarah Jane Ramos seemingly tunes out Cowboys’ brutal loss to 49ers

November 16, 2026
Facebook X (Twitter) Pinterest WhatsApp TikTok Instagram
© 2026 USA Times. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.